2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1572

Relationship Between KDR (VEGFR2) Gene Polymorphisms and Serum KDR Protein Levels in Patients with Rheumatoid Arthritis
Abstract Number: 1573

Major Histocompatibility Antigen HLA-DQ6.1 (DQA1*0103/DQB1*0601) Increases Rheumatoid Arthritis Risk Independent of Shared Epitope Among Indians
Abstract Number: 1574

The Role of Shelterin Deficiency in the Senescence in T Cells of Rheumatoid Arthritis
Abstract Number: 1575

Transient Circulatory Existence of Multipotential Stromal Cells Is Unlikely to Contribute to the Pathogenesis of Rheumatoid Arthritis
Abstract Number: 1576

Identifying Rheumatoid Arthritis Subtypes Using Synovial Tissue Gene Expression Profiling, Histologic Scoring and Clinical Correlates
Abstract Number: 1577

An Investigation of Translocator Protein As a Tissue and Peripheral Blood Biomarker of Inflammation in Rheumatoid Arthritis
Abstract Number: 1578

Functional Screening of Micrornas Using the Inhibitor Library Identified Micrornas to Regulate Expression of MMP-3 and IL-6 in Rheumatoid Arthritis Synovial Fibroblasts
Abstract Number: 1579

Small Rnaseq Reveals Different Plasma miRNA Signature in Patients with RA and SLE: A Pilot Study
Abstract Number: 1580

Impact of Rituximab on Patient-Reported Outcomes in Patients with Rheumatoid Arthritis from the US Corrona Registry
Abstract Number: 1581

The Combination of IL-6 and IL-6 Receptor Levels As a Biomarker of Response to Tocilizumab in Rheumatoid Arthritis Patients
Abstract Number: 1582

Assessment of Safety, Pharmacokinetics and Pharmacodynamics of a Novel Anti-CD40 Monoclonal Antibody, CFZ533, in Healthy Volunteers and in Rheumatoid Arthritis Patients
Abstract Number: 1583

Body Mass Index Does Not Affect Response to Subcutaneous or Intravenous Abatacept in Patients with Rheumatoid Arthritis
Abstract Number: 1584

Bari-00074565
Abstract Number: 1585

Previous Use of Conventional Disease-Modifying Antirheumatic Drugs and Response to Baricitinib
Abstract Number: 1586

Efficacy and Safety of Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs: A United States Subpopulation Analysis from Two Phase 3 Trials

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].